Celldex Therapeutics Inc. (CLDX): Today's Featured Drugs Laggard

Celldex Therapeutics ( CLDX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Celldex Therapeutics fell $0.40 (-2.0%) to $19.55 on average volume. Throughout the day, 1,715,986 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 1,860,800 shares. The stock ranged in price between $19.20-$20.33 after having opened the day at $20.23 as compared to the previous trading day's close of $19.95. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 34.5%, Merrimack Pharmaceuticals ( MACK), down 28.0%, Inovio Pharmaceuticals ( INO), down 11.6% and CytRx Corporation ( CYTR), down 8.1%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 197.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

On the positive front, Rexahn Pharmaceuticals ( RNN), up 16.8%, Alnylam Pharmaceuticals ( ALNY), up 15.8%, Rockwell Medical ( RMTI), up 15.7% and Bacterin International Holdings ( BONE), up 14.9% , were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today